Clinical Trial Update: A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age [Phase 1]

View source ↗

Summary

Phase 1 study evaluating single-dose pharmacokinetics and safety of ceftobiprole in pediatric patients aged 3 months to under 18 years. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcal Skin Infections
• Streptococcal Infections

Drugs mentioned

• ceftobiprole (ceftobiprole)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Staphylococcal Skin Infections, Streptococcal Infections | Phase 1 | Status: COMPLETED